Semaglutide denied as non-formulary by Cigna?

Cigna's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Deny Semaglutide as Non-Formulary

A non-formulary denial means semaglutide is not included on the specific drug tier list (formulary) associated with your Cigna health plan, or that it appears on a restricted tier requiring additional authorization that was not obtained. Formularies vary significantly between Cigna plan types — employer-sponsored plans, individual marketplace plans, and Medicare Advantage plans each maintain different formularies — and they are updated annually. A drug that was covered last year may be non-formulary this year due to a formulary change.

## Why This Denial Is Appealable

Non-formulary status is not the end of the road. Most plans offer a formulary exception process, and federal law provides a pathway to challenge coverage denials even when the drug is genuinely off-formulary. A formulary exception can be granted when the formulary alternatives are clinically inappropriate for your specific situation — for example, because you tried them and they failed, because they are contraindicated (as documented by your prescriber), or because your condition has specific features that make semaglutide the appropriate choice.

## Your Federal Appeal Rights

• Formulary exception request: Before or alongside a formal appeal, submit a formulary exception request with clinical documentation explaining why formulary alternatives are inadequate for you.
• Internal appeal: You have the right to a full-and-fair internal review of any adverse benefit determination under ERISA §503 or applicable state law. File within the timeframe on your denial notice.
• External review: Under ACA §2719, if the internal appeal is denied, an independent review organization (IRO) may review whether the non-formulary denial is appropriate given your clinical circumstances. The external-review window is generally approximately four months from the final internal denial; confirm the exact date on your denial letter.
• Expedited option: Request expedited review if your health would be seriously jeopardized by the standard timeline.

## Documentation to Gather

1. List of formulary alternatives: Obtain from Cigna the specific formulary alternatives they expect to be tried first. Your appeal will address each one by name. 2. Prior treatment with formulary alternatives: Chart documentation showing that you have already tried the formulary alternatives, including start dates, duration, outcomes, and reasons for discontinuation. 3. Clinical rationale for inaccessibility: If you have not tried a formulary alternative because your prescriber believes it is clinically inappropriate for you (due to your specific comorbidities, prior reactions, or other documented clinical factors), a detailed prescriber letter is required. 4. Prescriber medical-necessity letter: Explicitly stating why semaglutide — and not the formulary alternatives — is medically necessary for your care. 5. FDA prescribing information: The FDA-approved label for semaglutide and for each formulary alternative, to support any comparison your prescriber makes.

## Criteria-Mapping Structure

Pull Cigna's formulary exception criteria from their published policy or member handbook. Address each criterion directly:

| Formulary Exception Criterion | Your Supporting Evidence | |-------------------------------|-------------------------| | Tried and failed formulary alternative #1 | [Drug name, dates, documented outcome] | | Tried and failed formulary alternative #2 | [Drug name, dates, documented outcome] | | Clinical reason formulary alternative is inappropriate | [Prescriber letter citing specific clinical basis] | | Semaglutide is the appropriate agent for this patient | [Prescriber attestation referencing diagnosis and clinical history] |

A formulary exception that addresses every criterion with documented chart evidence is far more likely to succeed than a general request for coverage.